PubRank

D F Nixon

Author PubWeight™ 97.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998 12.05
2 Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991 10.85
3 HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000 5.79
4 An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001 4.79
5 Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999 3.79
6 Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999 3.00
7 Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991 2.83
8 High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol 1990 2.71
9 HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993 2.71
10 HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999 2.42
11 The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999 2.27
12 Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 2001 1.89
13 Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol 2001 1.68
14 Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol 1999 1.63
15 The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001 1.46
16 Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. AIDS 2000 1.45
17 A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001 1.41
18 Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992 1.38
19 Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000 1.33
20 Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27. Int Immunol 1990 1.31
21 Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol 2000 1.31
22 Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology 2001 1.23
23 The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis 2000 1.15
24 High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J Infect Dis 2000 1.14
25 Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. AIDS 2000 1.08
26 Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis 2000 1.07
27 Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus. Virology 2000 1.03
28 Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis 1999 1.03
29 Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philos Trans R Soc Lond B Biol Sci 2000 1.01
30 The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children. J Infect Dis 2000 0.99
31 Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells. J Virol 2000 0.97
32 Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol 2008 0.96
33 Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS 2000 0.95
34 Characterization of HIV-1-specific cytotoxic T lymphocytes expressing the mucosal lymphocyte integrin CD103 in rectal and duodenal lymphoid tissue of HIV-1-infected subjects. Virology 2000 0.95
35 Routine full blood counts as indicators of acute viral infections. J Clin Pathol 1987 0.92
36 Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators. J Infect Dis 1998 0.89
37 A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-specific CD8 T cells. AIDS 2001 0.89
38 Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol 2001 0.88
39 Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol 2001 0.87
40 Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease. Clin Exp Immunol 2009 0.86
41 Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol 2007 0.86
42 Brain Ia antigens have a bone marrow origin. Immunogenetics 1983 0.86
43 Human immunodeficiency virus variants that escape cytotoxic T-cell recognition. AIDS Res Hum Retroviruses 1992 0.86
44 Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. AIDS Res Hum Retroviruses 2000 0.86
45 T-cell strategies in AIDS vaccines: MHC-restricted T-cell responses to HIV proteins. AIDS 1989 0.82
46 HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA. HIV Med 2013 0.79
47 NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection. Scand J Immunol 2011 0.79
48 Isolation of cytomegalovirus-specific cytotoxic T-lymphocytes from gut-associated lymphoid tissue (GALT) of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 2000 0.78
49 Lymphocyte-mediated cytotoxicity against allogeneic tumour cells. IV. Fine specificity mapping and characterization of concanavalin A-activated cytotoxic effector lymphocytes. Immunology 1981 0.78
50 Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 2000 0.77
51 Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infection. Scand J Immunol 2004 0.77
52 Rational peptide selection to detect human immunodeficiency virus type 1-specific T-cell responses under resource-limited conditions. Clin Vaccine Immunol 2007 0.77
53 Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 1996 0.76
54 Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursors. Immunol Lett 1999 0.76
55 CTL induction using synthetic peptides delivered in emulsions--critical role of the formulation procedure. Vaccine 1997 0.75
56 Peripheral CD8+ T-cell levels are decreased in atopic wheezing children aged less than 4 years. J Investig Allergol Clin Immunol 2012 0.75
57 Cytotoxic T cell induction with ratchet peptide libraries. Vaccine 1996 0.75